

Study to assess the age-dependency in the clearance of doxorubicin in children with leukaemia and solid tumours

Submission date 02/09/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/09/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 29/03/2016	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/a-study-measuring-doxorubicin-blood-levels-in-children-young-people-having-treatment-for-solid-tumours-and-leukaemia-the-epoc-study>

Contact information

Type(s)

Scientific

Contact name

Dr Alison Steel

Contact details

Northern Institute of Cancer Research
Paul O'Gorman Building
Framlington Place
Newcastle Upon Tyne
United Kingdom
NE2 4HH

Additional identifiers

Clinical Trials Information System (CTIS)

2009-011454-17

ClinicalTrials.gov (NCT)

NCT01095926

Protocol serial number

8609

Study information

Scientific Title

Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia

Study objectives

Doxorubicin is widely used in the treatment of children's cancer, but little is known about how rapidly the drug is metabolised and removed from the body, particularly in very young children. The study brings together investigators in the UK, in France, Germany and Italy to investigate whether the rate of metabolism and removal is related to age or to the toxicity caused by treatment with doxorubicin. Because children's cancer is relatively rare, in order to recruit sufficient patients it is necessary to run the study in multiple clinical centres across four different countries. This study is funded by the FP7-programme of the European Union, specifically to obtain information on drugs like doxorubicin, where the drug is widely-used, but there are gaps in our knowledge.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Sunderland Research Ethics Committee, 26/04/2010, ref: 10/H090/22

Study design

Non-randomised, interventional and observational

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Paediatric Oncology, Leukaemia (acute), Leukaemia (chronic), Multiple Sites, Leukaemia (acute myeloid), Leukaemia (acute lymphoblastic), Leukaemia (acute promyelocytic)

Interventions

1. Collection of blood sample for genetic analysis
2. Collection of blood samples for drug and toxicity marker analysis

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Doxorubicin

Primary outcome(s)

The primary outcome will be when the data has been collected & analysed from all the 100 patients at the end of the study.

1. Pharmacokinetic data to enable assessment of age-dependency of doxorubicin in paediatric patients
2. Pharmacokinetic data available on 100 paediatric patients including at least 5 patients <1 year old

Key secondary outcome(s)

The outcome of an interim analysis on the data from the first 30 patients is expected to be reported early 2012

Completion date

28/02/2012

Eligibility

Key inclusion criteria

1. Patients less than or equal to 17 years of age
2. Plan to receive at least 2 cycles of doxorubicin
3. Must be enrolled in a national or European protocol for treatment of Wilms 4.Turmoours, Neuroblastoma, Soft tissue sarcome, Ewing Sarcoma or Acute lymphoblastic leukaemia and must be treated with doxorubicin according to that protocol or patients under 3 years enrolled or listed in any national or European study protocol for any paediatric malignancy.
5. Patients, parents or legal representative(s) must provide written informed consent to participate in the trial according to national regulations
6. Patients that are able to understand should provide assent to participate in the trial
7. Life expectancy is >3 months
8. Karnofsky performance status of $\geq 70\%$
9. Additional blood withdrawal is acceptable to the patient. (the decision is left to the investigator)
10. Either male or female

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Upper age limit

17 years

Sex

All

Key exclusion criteria

Prior cardiac problems

Date of first enrolment

16/01/2011

Date of final enrolment

28/02/2012

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Northern Institute of Cancer Research

Newcastle Upon Tyne

United Kingdom

NE2 4HH

Sponsor information

Organisation

Newcastle upon Tyne Hospitals NHS Trust (UK)

ROR

<https://ror.org/05p40t847>

Funder(s)

Funder type

Government

Funder Name

Commission of the European Communities (Europe)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2015		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes